Skip to content
Screener

Denali Therapeutics Inc. DNLI Q3 2025 earnings

Reported November 6, 2025 · Before market open

EPS-$0.74Beat by $0.02
Revenue estimate$2.9M
EPS estimate-$0.76

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$12.2M
EPS estimate-$0.37

Financials

Q3 2025

Income statement

See full
Operating income-$137.4M-11.6%
Net income-$126.9M-18.4%
EPS (diluted)-$0.74-17.5%

Balance sheet

See full
Cash & equivalents$94.1M+2.0%
Total debt$44.5M-15.4%
Total equity$926.2M-29.8%
Total assets$1.1B-27.4%

Cash flow

See full
Operating cash flow-$107.3M-81.4%
Free cash flow-$105.9M-68.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.12B-49.1%
Enterprise value$2.07B-49.8%

Returns & leverage

See full
Return on equity-44.4%+16.1pp
Debt / equity0×0.0×
Current ratio9.8×-0.2×

Segments

By product

See full
Milestone Triggered$25.0M—
CNS Product$16.3M0.0%
Milestone Payment$2.5M0.0%
Option Fee Payment$1.3M0.0%

By segment

See full
Therapeutics Segment-—

FAQ

When did Denali Therapeutics Inc. report Q3 2025 earnings?
Denali Therapeutics Inc. (DNLI) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Denali Therapeutics Inc.'s Q3 2025 revenue and EPS?
Denali Therapeutics Inc. reported eps of $-0.74 for Q3 2025.
Did Denali Therapeutics Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.76 by $0.02.
How did Denali Therapeutics Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 17.5% from $-0.63.
Where can I find Denali Therapeutics Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001714899-25-000192) and the 10-Q periodic report (0001714899-25-000193) directly on SEC EDGAR. The filing index links above go to sec.gov.